ABT vs NPCE
ABT: Abbott Laboratories is a diversified healthcare giant providing a broad portfolio of diagnostic systems, medical devices, nutritional products, and established branded generic pharmaceuticals. NPCE: NeuroPace makes the RNS System, the only FDA-approved brain-responsive neuromodulation device that monitors and treats drug-resistant epilepsy by delivering personalized electrical stimulation directly at seizure sources.
Side-by-side fundamentals
| Metric | ABT | NPCE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $100.57 | $14.58 | |
| Market cap as of 2026-07-23 | $175.1B | $497M | |
| P/E as of 2026-07-23 | 32.28 | n/a | |
| PEG as of 2026-07-23 | 2.66 | n/a | |
| Net margin as of 2026-07-23 | +11.7% | -21.7% | ABT higher |
| Gross margin as of 2026-07-23 | +56.8% | +78.3% | NPCE higher |
| Operating margin as of 2026-07-23 | +15.8% | -17.3% | ABT higher |
| ROE as of 2026-07-23 | +12.2% | -120.7% | ABT higher |
| ROA as of 2026-07-23 | +6.9% | -20.6% | ABT higher |
| Debt / equity as of 2026-07-23 | 0.65 | 4.08 | ABT lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.1% | +18.1% | NPCE higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +30.0% | NPCE higher |
| Dividend yield as of 2026-07-23 | +2.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | 0 | ABT higher |
| Beta as of 2026-07-23 | 0.59 | 1.96 | |
| 1-year return as of 2026-07-22 close | -20.0% | +65.2% | NPCE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.